Issue 2/2022
Content (9 Articles)
Clozapine
Current Opinion
Alternative Routes of Administration of Clozapine
Siobhan Gee, David Taylor
Epilepsy
Leading Article
Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine?
Meir Bialer, Emilio Perucca
Potential Role of Curcumin for the Treatment of Major Depressive Disorder
Adrian L. Lopresti
Frontotemporal Dementia
Review Article
Pharmacological Management of Apathy in Dementia
Laiba Azhar, Raphael W. Kusumo, Giovanni Marotta, Krista L. Lanctôt, Nathan Herrmann
Metastasis
Review Article
Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies
Lauren Chiec, Priya Kumthekar
Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model
Drew MacCannell, Zdenek Berger, Janbernd Kirschner, Eugenio Mercuri, Michelle A. Farrar, Susan T. Iannaccone, Nancy L. Kuntz, Richard S. Finkel, Marta Valente, Francesco Muntoni
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score
Luigi Francesco Iannone, Davide Fattori, Silvia Benemei, Alberto Chiarugi, Pierangelo Geppetti, Francesco De Cesaris
Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status“
Marco Pappagallo, Charles E. Inturrisi, Paolo L. Manfredi
Mood Disorders
Letter to the Editor
Authors’ Reply to Pappagallo et al.: Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status”
Ioline D. Henter, Lawrence T. Park, Carlos A. Zarate Jr.